NI-603

NI-603 is a preclinical **monoclonal antibody** program attributed in public drug-pipeline aggregators to **Neurimmune** for treatment of **nervous system diseases** and more broadly **pathological protein aggregation** disorders. Publicly accessible sources verify the existence of the program name and its association with Neurimmune, but they do **not** clearly disclose a confirmed molecular target, epitope, or precise indication. Based on Neurimmune's broader strategy in protein-misfolding diseases, NI-603 appears to be an investigational antibody intended to engage aggregated or misfolded protein species, but the exact mechanism of action for this specific asset is not publicly established from accessible primary-source detail.